Brean

Chimerix Inc (NASDAQ: CMRX)'s proposed government contract to produce up to 1.7 million doses of a treatment for smallpox could be worth up to $435 million, an analyst said Wednesday. The company was awarded the sole-source, five-year contract Monday, although it would formally receive it until...

Axiom initiated coverage on LinkedIn Corp (NYSE: LNKD) Friday with a Buy rating and $300 price target. Analyst Victor Anthony felt that Sales Navigator had a "long runway" with less than 2 percent penetration and noted that it could generate $230 million in revenue for 2015....

Activision Blizzard, Inc. (NASDAQ: ATVI) reports Q4 earnings Thursday. The Street expects revenue of $2.24 billion and EPS of $0.88. Wedbush expected revenue of $2.275 million and EPS of $0.91 with flat Q4 sales and FY 2015 guidance to come in above expectations. The firm maintained an...

Brean Capital reiterated its Sell rating on Rockwell Medical Inc (NASDAQ: RMTI) on Monday following the FDA approval of its Triferic iron replacement product. The firm maintained a $4 price target. Analysts Jonathan Aschoff and Yi Cheng expected “dismal commercial uptake” for the...

Broadcom Corporation (NASDAQ: BRCM) announced a range of shareholder-focused initiatives at its annual Analyst Day on Tuesday. The stock responded by trading higher Wednesday morning with shares surging over 2 percent to $43.64. Below are highlights from analyst comments following the meeting...

Analysts commented on 3D Systems Corporation (NYSE: DDD) after it posted mixed Q3 results Monday. Shares fell Tuesday afternoon to $34.62, down 4.4 percent. Below are analyst comments along with current ratings and price targets. Citi - Neutral, $40 price target “3D Systems...

Activision Blizzard, Inc. (NASDAQ: ATVI) will face difficult revenue comparisons next year because of the currently strong performance of its "Destiny" video game product, an analyst said Wednesday. Activision beat third-quarter expectations Tuesday, citing its newly launched "...

3D Systems (NYSE: DDD) reported earnings after Thursday's close. Second quarter Q2 EPS and revenues both came in below consensus estimates. Revenue for the quarter was $151.5 million versus a consensus of $162.2 million; organic growth for the quarter was only 10 percent. Non-GAAP EPS...

3-D printing stocks are trading lower again in sympathy after ExOne (NASDAQ: XONE) reported downbeat fourth quarter results and issued a weak 2014 revenue outlook on Wednesday afternoon. Brean Capital sees the sector weakness as a sector buying opportunity and RBC had some bullish comments on the...

Shares of Guess? (NYSE: GES) are up 1.8 percent to $29 in the face of a bearish note from Brean Capital. Eric Beder, analyst at Brean, lowered his fourth quarter 2014 earnings per share estimates to $0.69 from $0.80, well below management's EPS guidance of $0.74-$0.84 and the Street consensus...

Brean, Murray, Carret & Co. analyst Ananda Baruah reiterated a Buy rating for shares of Xyratex Ltd. (NASDAQ: XRTX), with a price target of $24 per share. Baruah recommended buying aggressively during unwarranted sell-offs of Xyratex Ltd. stock. The analyst noted that shares of Xyratex Ltd....

Brean, Murray, Carret & Co. analyst Ingrid Yin maintained her Buy rating for shares of China Biologic Products, Inc. (Nasdaq: CBPO) and raised the price target to $20 per share, from the previous price target of $19. The analysts said that China Biologic Products, Inc. had announced that the...